

# Fleur Cohen Aubart

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6037377/publications.pdf>

Version: 2024-02-01

83  
papers

4,766  
citations

147801

31  
h-index

98798

67  
g-index

120  
all docs

120  
docs citations

120  
times ranked

4669  
citing authors

#	ARTICLE	IF	CITATIONS
1	Correspondence on "Glucocorticoid-induced relapse of COVID-19 in a patient with sarcoidosis"™. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e241-e241.	0.9	10
2	BNT162b2 vaccine-induced humoral and cellular responses against SARS-CoV-2 variants in systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 575-583.	0.9	61
3	High frequency of clonal hematopoiesis in Erdheim-Chester disease. <i>Blood</i> , 2021, 137, 485-492.	1.4	30
4	Are script concordance tests suitable for the assessment of undergraduate students? A multicenter comparative study. <i>Revue De Medecine Interne</i> , 2021, 42, 243-250.	1.0	8
5	Clinical phenotypes of extrapulmonary sarcoidosis: an analysis of a French, multi-ethnic, multicentre cohort. <i>European Respiratory Journal</i> , 2021, 57, 2001160.	6.7	29
6	Development and clinical validation of a simple and fast UPLC-ESI-MS/MS method for simultaneous quantification of nine kinase inhibitors and two antiandrogen drugs in human plasma: Interest for their therapeutic drug monitoring. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2021, 197, 113968.	2.8	15
7	Peritoneal or mesenteric tumours revealing histiocytosis. <i>BMJ Open Gastroenterology</i> , 2021, 8, e000622.	2.7	3
8	Histiocytosis and the nervous system: from diagnosis to targeted therapies. <i>Neuro-Oncology</i> , 2021, 23, 1433-1446.	1.2	33
9	Progressive clinical case-based multiple-choice questions: An innovative way to evaluate and rank undergraduate medical students. <i>Revue De Medecine Interne</i> , 2021, 42, 302-309.	1.0	2
10	Immune Thrombocytopenia Revealing Enriched IgG-4 Peri-Renal Rosai-Dorfman Disease Successfully Treated with Rituximab: A Case Report and Literature Review.. <i>Frontiers in Medicine</i> , 2021, 8, 678456.	2.6	3
11	Histiocytosis. <i>Lancet, The</i> , 2021, 398, 157-170.	13.7	58
12	Nonsystemic vasculitic neuropathy: Presentation and long-term outcome from a French cohort of 50 patients. <i>Autoimmunity Reviews</i> , 2021, 20, 102874.	5.8	2
13	IgG4-related disease and Rosai-Dorfman-Destombes disease " Authors' reply. <i>Lancet, The</i> , 2021, 398, 1214-1215.	13.7	0
14	Exposure to inorganic particles in paediatric sarcoidosis: the PEDIASARC study. <i>Thorax</i> , 2021, , thoraxjnl-2021-217870.	5.6	10
15	Case Report: Evolution of a Severe Vascular Refractory Form of ECD Requiring Liver Transplantation Correlated With the Change in the Monocyte Subset Analysis. <i>Frontiers in Immunology</i> , 2021, 12, 755846.	4.8	2
16	Erdheim-Chester disease with concomitant Rosai-Dorfman like lesions: a distinct entity mainly driven by <i>MAP2K1</i> . <i>Haematologica</i> , 2020, 105, e5-e8.	3.5	34
17	Lung Involvement in Destombes-Rosai-Dorfman Disease. <i>Chest</i> , 2020, 157, 323-333.	0.8	17
18	The eclipse sign as a radiological presentation of neurosarcoidosis. <i>International Journal of Neuroscience</i> , 2020, 130, 435-437.	1.6	1

#	ARTICLE	IF	CITATIONS
19	Drug-induced sarcoidosis: an overview of the WHO pharmacovigilance database. <i>Journal of Internal Medicine</i> , 2020, 288, 356-362.	6.0	61
20	Diagnosis issues in sarcoidosis. <i>Respiratory Medicine and Research</i> , 2020, 77, 37-45.	0.6	15
21	Coronary artery disease in systemic lupus: A case-controlled angiographic study. <i>Autoimmunity Reviews</i> , 2020, 19, 102427.	5.8	5
22	Workload, well-being and career satisfaction among French internal medicine physicians and residents in 2018. <i>Postgraduate Medical Journal</i> , 2020, 96, 21-27.	1.8	4
23	Cognitive dysfunction and brain atrophy in Susac syndrome. <i>Journal of Neurology</i> , 2020, 267, 994-1003.	3.6	13
24	Spectrum and Prognosis of Antineutrophil Cytoplasmic Antibody-associated Vasculitis-related Bronchiectasis: Data from 61 Patients. <i>Journal of Rheumatology</i> , 2020, 47, 1522-1531.	2.0	10
25	Response to: "Efficacy and improved tolerability of combination therapy with interleukin-1 blockade and MAPK pathway inhibitors for the treatment of Erdheim-Chester disease" by Campochiaro et al. <i>Annals of the Rheumatic Diseases</i> , 2020, , annrheumdis-2019-216755.	0.9	1
26	Central nervous system involvement in Erdheim-Chester disease. <i>Neurology</i> , 2020, 95, e2746-e2754.	1.1	22
27	Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 837-839.	0.9	208
28	Sarcoidosis diagnosed on granulomas in the explanted heart after transplantation: Results of a French nationwide study. <i>International Journal of Cardiology</i> , 2020, 307, 94-100.	1.7	10
29	Women's representation in French Internal Medicine meetings: gender distribution among speakers, moderators and organisers, 2013-2018. <i>Internal Medicine Journal</i> , 2020, 50, 477-480.	0.8	2
30	Erdheim-Chester disease. <i>Blood</i> , 2020, 135, 1311-1318.	1.4	99
31	Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era. <i>Blood</i> , 2020, 135, 1929-1945.	1.4	191
32	Diabetes Mellitus, Extreme Insulin Resistance, and Hypothalamic-Pituitary Langerhans Cells Histiocytosis. <i>Case Reports in Endocrinology</i> , 2019, 2019, 1-8.	0.4	1
33	Ultrasensitive serum interferon- $\gamma$ quantification during SLE remission identifies patients at risk for relapse. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1669-1676.	0.9	59
34	Long-bones involvement in generalized crystal-storing histiocytosis. <i>Joint Bone Spine</i> , 2019, 86, 652-653.	1.6	3
35	Atteintes ostéoarticulaires au cours des histiocytoses. <i>Revue Du Rhumatisme Monographies</i> , 2019, 86, 120-125.	0.0	0
36	Systemic Histiocytosis (Langerhans Cell Histiocytosis, Erdheim-Chester Disease,) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 67 Td (Destom Oncology Reports</i> , 2019, 21, 62.	4.0	48

#	ARTICLE	IF	CITATIONS
37	Sarcoidosis occurring during <sc>BRAF</sc>/<sc>MEK</sc> inhibitors is associated with paradoxical <sc>ERK</sc> activation in Erdheim-Chester patients. Journal of the European Academy of Dermatology and Venereology, 2019, 33, e348-e350.	2.4	7
38	The cerebrospinal fluid <sc>CD</sc>4/<sc>CD</sc>8 ratio and interleukin-6 and -10 levels in neurosarcoidosis: a multicenter, pragmatic, comparative study. European Journal of Neurology, 2019, 26, 1274-1280.	3.3	28
39	Women in internal medicine academic positions in France. European Journal of Internal Medicine, 2019, 64, e18-e20.	2.2	2
40	Autoimmunity associated with Erdheim-Chester disease improves with BRAF/MEK inhibitors. Haematologica, 2019, 104, e502-e505.	3.5	15
41	Infliximab biosimilar for treating neurosarcoidosis: tolerance and efficacy in a retrospective study including switch from the originator and initiation of treatment. Journal of Neurology, 2019, 266, 1073-1078.	3.6	18
42	Monitoring Disease Activity in Systemic Lupus Erythematosus With Single-Molecule Array Digital Enzyme-Linked Immunosorbent Assay Quantification of Serum Interferon- $\gamma$ . Arthritis and Rheumatology, 2019, 71, 756-765.	5.6	51
43	Les événements cardiovasculaires sont associés à une diminution de la survie chez les patients avec une artérite à cellules géantes: étude cas-témoin multicentrique. Revue Du Rhumatisme (Edition) Tj ETQq.1 0.784314 rgB	1.4	2
44	High Serum VEGF Level in Erdheim-Chester Disease: Correlation with Cardiovascular Involvement and Response to Treatment. Blood, 2019, 134, 2324-2324.	1.4	2
45	Cerebrovascular events in Takayasu arteritis: a multicenter case-controlled study. Journal of Neurology, 2018, 265, 757-763.	3.6	31
46	Phenotypes and survival in Erdheim-Chester disease: Results from a 165-patient cohort. American Journal of Hematology, 2018, 93, E114-E117.	4.1	94
47	Efficacy of infliximab in the treatment of Erdheim-Chester disease. Annals of the Rheumatic Diseases, 2018, 77, 1387-1390.	0.9	22
48	Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease. Blood, 2018, 131, 2877-2890.	1.4	335
49	Efficacy of the <sc>MEK</sc> inhibitor cobimetinib for wild-type <sc>BRAF</sc> Erdheim-Chester disease. British Journal of Haematology, 2018, 180, 150-153.	2.5	55
50	Cerebrovascular events are associated with lower survival in giant cell arteritis: A case-controlled multicenter study. Joint Bone Spine, 2018, 85, 383-385.	1.6	11
51	Clinical, histological, immunological presentations and outcomes of bullous systemic lupus erythematosus: 10 New cases and a literature review of 118 cases. Seminars in Arthritis and Rheumatism, 2018, 48, 83-89.	3.4	57
52	Incidence and risk factors for clinical neurodegenerative Langerhans cell histiocytosis: a longitudinal cohort study. British Journal of Haematology, 2018, 183, 608-617.	2.5	54
53	Giant-cell arteritis-related mortality in France: A multiple-cause-of-death analysis. Autoimmunity Reviews, 2018, 17, 1219-1224.	5.8	17
54	Clinical, imaging, and histological presentations and outcomes of stroke related to sarcoidosis. Journal of Neurology, 2018, 265, 2333-2341.	3.6	25

#	ARTICLE	IF	CITATIONS
55	PD-1/ PD-L1 Expression Is Associated with Tissue Inflammation and BRAF Status in Erdheim-Chester Disease. <i>Blood</i> , 2018, 132, 4380-4380.	1.4	0
56	Histiocytoses: emerging neoplasia behind inflammation. <i>Lancet Oncology</i> , The, 2017, 18, e113-e125.	10.7	154
57	Efficacy and safety of tumor necrosis factor antagonists in refractory sarcoidosis: A multicenter study of 132 patients. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 47, 288-294.	3.4	81
58	Long-term outcomes of refractory neurosarcoidosis treated with infliximab. <i>Journal of Neurology</i> , 2017, 264, 891-897.	3.6	90
59	Successful outcome of proliferative lupus nephritis during pregnancy: Toward a modern paradigm of lupus pregnancy?. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2017, 214, 201-203.	1.1	0
60	Clinicopathological features of multiple mononeuropathy associated with systemic lupus erythematosus: a multicenter study. <i>Journal of Neurology</i> , 2017, 264, 1218-1226.	3.6	23
61	Functional evidence for derivation of systemic histiocytic neoplasms from hematopoietic stem/progenitor cells. <i>Blood</i> , 2017, 130, 176-180.	1.4	98
62	Cerebral pseudo-tumoral neuro-Behcet: Histological demonstration of an inflammatory and vascular disease. <i>Clinical Neurology and Neurosurgery</i> , 2017, 161, 48-50.	1.4	10
63	Targeted therapies in 54 patients with Erdheim-Chester disease, including follow-up after interruption (the LOVE study). <i>Blood</i> , 2017, 130, 1377-1380.	1.4	146
64	Spinal Koebner phenomenon: Medullar sarcoidosis facing a discal hernia. <i>Joint Bone Spine</i> , 2017, 84, 497-498.	1.6	7
65	Pulmonary hyalinizing granuloma: a multicenter study of 5 new cases and review of the 135 cases of the literature. <i>Immunologic Research</i> , 2017, 65, 375-385.	2.9	30
66	<i>BRAF</i> Mutation Correlates With High-Risk Langerhans Cell Histiocytosis and Increased Resistance to First-Line Therapy. <i>Journal of Clinical Oncology</i> , 2016, 34, 3023-3030.	1.6	233
67	Variability in the efficacy of the IL1 receptor antagonist anakinra for treating Erdheim-Chester disease. <i>Blood</i> , 2016, 127, 1509-1512.	1.4	49
68	Relapsing polychondritis: A 2016 update on clinical features, diagnostic tools, treatment and biological drug use. <i>Best Practice and Research in Clinical Rheumatology</i> , 2016, 30, 316-333.	3.3	79
69	Shrinking lung syndrome associated with systemic lupus erythematosus: A multicenter collaborative study of 15 new cases and a review of the 155 cases in the literature focusing on treatment response and long-term outcomes. <i>Autoimmunity Reviews</i> , 2016, 15, 994-1000.	5.8	48
70	Treatment of neurosarcoidosis. <i>Neurology</i> , 2016, 87, 2517-2521.	1.1	82
71	Plasma Chromogranin A as a marker of cardiovascular involvement in Erdheim-Chester disease. <i>Oncolmmunology</i> , 2016, 5, e1181244.	4.6	14
72	Cutaneous manifestations of Erdheim-Chester disease (ECD): Clinical, pathological, and molecular features in a monocentric series of 40 patients. <i>Journal of the American Academy of Dermatology</i> , 2016, 74, 513-520.	1.2	64

#	ARTICLE	IF	CITATIONS
73	Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms. <i>Cancer Discovery</i> , 2016, 6, 154-165.	9.4	372
74	Recurrent BRAF mutations in bone marrow progenitors of patients with Erdheim-Chester disease.. <i>Journal of Clinical Oncology</i> , 2016, 34, 7069-7069.	1.6	0
75	Treatment of Erdheim-Chester disease patients with the MEK inhibitor cobimetinib.. <i>Journal of Clinical Oncology</i> , 2016, 34, e19074-e19074.	1.6	0
76	SAT0549â€¦Methotrexate Versus Mycophenolate Mofetil in Neurosarcoidosis: A Retrospective Trial. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 859.1-859.	0.9	0
77	Reproducible and Sustained Efficacy of Targeted Therapy With Vemurafenib in Patients With <i>BRAF</i> <sup>V600E</sup> -Mutated Erdheim-Chester Disease. <i>Journal of Clinical Oncology</i> , 2015, 33, 411-418.	1.6	238
78	Vemurafenib as first line therapy in BRAF-mutated Langerhans cell histiocytosis. <i>Journal of the American Academy of Dermatology</i> , 2015, 73, e29-e30.	1.2	22
79	Right Ventricular Hypertrophy Along With Malignant Ventricular Arrhythmias. <i>Circulation</i> , 2015, 132, e170-5.	1.6	1
80	Erdheimâ€“Chester Disease. <i>Current Rheumatology Reports</i> , 2014, 16, 412.	4.7	110
81	Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease. <i>Blood</i> , 2014, 124, 3016-3019.	1.4	197
82	High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. <i>Blood</i> , 2012, 120, 2700-2703.	1.4	589
83	Spinal Cord Sarcoidosis. <i>Medicine (United States)</i> , 2010, 89, 133-140.	1.0	73